EV-derived platforms broaden safety and targeting: edible, cation-free kiwi EVs carrying STAT3 siRNA and an EGFR aptamer suppress drug-resistant EGFR-mutant NSCLC with superior tolerability to cationic liposomes [69]; engineered EV–gold nanohybrids deliver B7-H4 siRNA to NSCLC cells and spheroids, sparing normal fibroblasts and inhibiting xenografts [70]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.